Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab

Raanan Berger*, Gal Dinstag, Omer Tirosh, Eyal Schiff, David Kleiner, Kenneth D. Aldape, Eytan Ruppin, Tuvik Beker*, Razelle Kurzrock*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There is no clear standard of care for the disease, whose response to treatment seems to be very different from that of hepatocellular carcinoma. We present a case of FLC in a patient in her mid 30s that recurred and persisted despite resection and multiple lines of treatment. Following transcriptomic analysis, a combination of ipilimumab (anti-CTLA4) and nivolumab (anti-PD-1) led to complete remission, although common biomarkers for immune checkpoint blockade were all negative in this case. The patient is still in remission. Here, combined checkpoint blockade guided by novel transcriptomic analysis led to complete remission after failure of several lines of treatment.

Original languageEnglish
Article numbere005620
JournalJournal for ImmunoTherapy of Cancer
Volume10
Issue number12
DOIs
StatePublished - 9 Dec 2022
Externally publishedYes

Keywords

  • Biomarkers, Tumor
  • Genetic Markers
  • Immunotherapy
  • Liver Neoplasms

Fingerprint

Dive into the research topics of 'Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab'. Together they form a unique fingerprint.

Cite this